🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

STERIS plc (STE)

NYSE
Currency in USD
209.62
-4.60(-2.15%)
Closed
After Hours
216.44+6.82(+3.25%)
STE Scorecard
Full Analysis
High shareholder yield
Fair Value
Day's Range
209.38217.21
52 wk Range
197.82248.24
Key Statistics
Edit
Prev. Close
214.22
Open
214.95
Day's Range
209.38-217.21
52 wk Range
197.82-248.24
Volume
497.16K
Average Volume (3m)
560.27K
1-Year Change
6.21%
Book Value / Share
66.86
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
STE Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
249.39
Upside
+18.97%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 14 consecutive years
Show more

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.

STERIS plc SWOT Analysis


Infection Prevention
STERIS leads in healthcare infection control, with strategic focus driving growth in sterilization and procedural products amid increasing demand
Financial Resilience
Q1 FY2025 surpasses expectations with $1.28B revenue and $2.03 EPS, showcasing STERIS's ability to maintain growth post-Dental segment divestiture
Strategic Realignment
Dental segment sale for $800M reshapes STERIS's profile, allowing focus on core competencies and potential for operational efficiencies
Market Valuation
Analysts set price targets around $265, reflecting STERIS's premium position in MedTech sector, despite challenges in maintaining growth rates
Read full SWOT analysis
STE Full Pro Research
Institutional-Grade Stock Analysis
Understand how STE earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

STERIS plc Earnings Call Summary for Q4/2024

  • Q2 FY2025: Revenue up 7%, adjusted EPS rose 15% to $2.14; margins declined with gross at 43.7% and EBIT at 22.2%
  • Healthcare revenue +7%, AST +9%, Life Sciences +3%; capital equipment down 2% with $405M backlog
  • FY2025 guidance: 6-7% organic revenue growth, adjusted EPS $9.05-$9.25, free cash flow ~$700M
  • Strong recurring revenue in Healthcare; Asia Pacific growth, particularly Malaysia; active M&A pipeline
  • Challenges: Labor and energy costs, AST segment underperformance; capital equipment revenue expected flat to down
Last Updated: 08-11-2024, 05:28 pm
Read Full Transcript

Compare STE to Peers and Sector

Metrics to compare
STE
Peers
Sector
Relationship
P/E Ratio
35.0x77.7x−0.7x
PEG Ratio
−1.751.450.00
Price/Book
3.1x4.5x2.6x
Price / LTM Sales
3.9x4.1x3.2x
Upside (Analyst Target)
19.0%0.0%47.1%
Fair Value Upside
Unlock7.3%7.3%Unlock

Analysts' Recommendations

5 Buy
4 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 249.39

(+18.97% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.4
Dividend Yield
1.06%
Industry Median 0.73%
Annualised payout
2.2800
Paid quarterly
5-Years Growth
+8.91%
Growth Streak

FAQ

What Is the STERIS (STE) Stock Price Today?

The STERIS stock price today is 209.62.

What Stock Exchange Does STERIS Trade On?

STERIS is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for STERIS?

The stock symbol for STERIS is "STE."

Does STERIS Pay Dividends? What’s The Current Dividend Yield?

The STERIS dividend yield is 1.06%.

What Is the STERIS Market Cap?

As of today, STERIS market cap is 20.72B.

What is STERIS Earnings Per Share?

The STERIS EPS is 4.40.

What Is the Next STERIS Earnings Date?

STERIS will release its next earnings report on 04 Feb 2025.

From a Technical Analysis Perspective, Is STE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.